Neuropsychiatric Symptoms and Expenditure on Complementary and Alternative Medicine

DSpace/Manakin Repository

Neuropsychiatric Symptoms and Expenditure on Complementary and Alternative Medicine

Citable link to this page

 

 
Title: Neuropsychiatric Symptoms and Expenditure on Complementary and Alternative Medicine
Author: Purohit, Maulik Prafull; Zafonte, Ross Dennis; Sherman, Laura M.; Davis, Roger B.; Giwerc, Michelle Y.; Shenton, Martha Elizabeth ORCID  0000-0003-4235-7879 ; Yeh, Gloria Y.

Note: Order does not necessarily reflect citation order of authors.

Citation: Purohit, Maulik P., Ross D. Zafonte, Laura M. Sherman, Roger B. Davis, Michelle Y. Giwerc, Martha E. Shenton, and Gloria Y. Yeh. 2015. “Neuropsychiatric Symptoms and Expenditure on Complementary and Alternative Medicine.” The Journal of Clinical Psychiatry (July 22): e870–e876. doi:10.4088/jcp.13m08682.
Full Text & Related Files:
Abstract: Objective—Neuropsychiatric symptoms affect 37% of US adults. These symptoms are often refractory to standard therapies, and patients may consequently opt for complementary and alternative medicine therapies (CAM). We sought to determine the demand for CAM by those with neuropsychiatric symptoms compared to those without neuropsychiatric symptoms as measured by out-of-pocket expenditure. Method—We compared CAM expenditure between US adults with and without neuropsychiatric symptoms (n = 23,393) using the 2007 National Health Interview Survey. Symptoms included depression, anxiety, insomnia, attention deficits, headaches, excessive sleepiness, and memory loss. CAM was defined per guidelines from the National Institutes of Health as mind body therapies, biological therapies, manipulation therapies, or alternative medical systems. Expenditure on CAM by those without neuropsychiatric symptoms was compared to those with neuropsychiatric symptoms. Results—Of the adults surveyed, 37% had ≥ 1 neuropsychiatric symptom and spent $ 14.8 billion out-of-pocket on CAM. Those with ≥ 1 neuropsychiatric symptom were more likely than those without neuropsychiatric symptoms to spend on CAM (27.4% vs 20.3%, P < .001). Likelihood to spend on CAM increased with number of symptoms (27.2% with ≥ 3 symptoms, P < .001). After adjustment was made for confounders using logistic regression, those with ≥ 1
Published Version: doi:10.4088/JCP.13m08682
Other Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729567/
Terms of Use: This article is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:35644991
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters